Skip to main content

Cardio/Pulmonary

ICYMI: Community-Acquired Pneumonia (CAP) https://t.co/geb8y2AK26 https://t.co/cB3y5vQoz1
Dr. John Cush @RheumNow( View Tweet )
CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did not prevent (6.3% vs 6.5%; HR 0.98; 0.83 to 1.16) subsequent stroke within 90 days compared with placebo https://t.co/APiMYVkBTV https://t.co/VgFiCKfMqB
Dr. John Cush @RheumNow( View Tweet )
How do you manage new progressive ILD?

Dr. John Cush @RheumNow( View Tweet )

No Risk of Interstitial Lung Disease with Methotrexate Use JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM). https://t.co/qauRelAkG0 https://t.co/bhSLYrfzlv
Dr. John Cush @RheumNow( View Tweet )
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/NcxReWk83n https://t.co/FSMx22XiNo
Dr. John Cush @RheumNow( View Tweet )
TARGET compared triple DMARD to TNFi in 122 RA pts and association with CV risk. In a subanalysis they found no correlation between change in lipid measurements and change in vascular inflammation by FDG-PET. https://t.co/0HKogmdRGH https://t.co/cD7UVTgTQ3
Dr. John Cush @RheumNow( View Tweet )

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality

Read Article
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Dr. John Cush @RheumNow( View Tweet )

No Risk of Interstitial Lung Disease with Methotrexate Use

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
Another proof (if needed) that controlling Dz Activity in RA is a very important preventive measure in RA! 179 pts ILD newly developed 9.5% progressed 12.3% no change 74.9% improved 4.5% 5.7% in the LDA group 28.0% non-LDA group (p=0.006) #EULAR2024 POS0408 @AurelieRheumo https://t.co/lKUY32KFiX
Dr. John Cush @RheumNow( View Tweet )

Damage in Childhood Lupus

EurekAlert!

Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which could allow earlier

Read Article
Matters of the heart: cardiovascular disease and mortality in RA Patients with RA have up to 2x higher risk of coronary artery disease, plus increased atrial fibrillation and stroke risk. https://t.co/wFs7ds3tF2 https://t.co/GWyXJbeyIn
Dr. John Cush @RheumNow( View Tweet )

New Treatments for Systemic Sclerosis

EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. Two abstracts

Read Article

EULAR 2024 – Day 4 Report

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article

EULAR 2024 – Day 3 Report

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite

Read Article
POS1035 FVC & risk of lung transplant & mortality in #RAILD 50% pts had FVC % predicted decline in ~6.5yrs 2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression #EULAR2024 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow! 🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024 🔗 https://t.co/b639vE5hSA @MyasoedovaElena

Mrinalini Dey @DrMiniDey( View Tweet )

#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Matters of the heart: cardiovascular disease and mortality in RA

Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).

Read Article
#SARD #ILD Who to screen for #rheumatic #diseases For ILD #ACR guidelines Screening May also depend on ILD prevalence Not sure if frequency of screening and how to screen @jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Janet Pope @Janetbirdope( View Tweet )
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN

EULAR 2024 – Day 2 Report (A Difficult RA Day)

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Read Article
Poster tours at #EULAR2024. A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
Dr. Antoni Chan @synovialjoints( View Tweet )
Top 3 messages Re #JAKi #safety Shared decision w benefit/risk info Some #CV risks are more Impt than others- stratify your pt into risk categories #Smoking is a big risk for #MACE & #malignancy-So work on facilitating Smoking #cessation #EULAR2024 @eular_org @RheumNow

Janet Pope @Janetbirdope( View Tweet )

Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp
Dr Gurdeep S Dulay @gurdeep_dulay( View Tweet )